Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma.

Cancer immunology research - 3 May 2023

Yeo Alan T, Shah Rushil, Aliazis Konstantinos, Pal Rinku, Xu Tuoye, Zhang Piyan, Rawal Shruti, Rose Christopher M, Varn Frederick S, Appleman Vicky A, Yoon Joon, Varma Hemant, Gygi Steven P, Verhaak Roel G W, Boussiotis Vassiliki A, Charest Al

Abstract excerpt

The composition of the tumor immune microenvironment (TIME) is considered a key determinant of patients' response to immunotherapy. The mechanisms underlying TIME formation and development over time are poorly understood. Glioblastoma (GBM) is a lethal primary brain cancer for which there are no curative treatments. GBMs are immunologically heterogeneous and impervious to checkpoint blockade immunotherapies....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CTLA-4 Antigen

Share to Glioblastoma

Share to Immunotherapy

Share to Myeloid-Derived Suppressor Cells

Share to Programmed Cell Death 1 Receptor

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 36881002
DOI: 10.1158/2326-6066.CIR-22-0655
PMCID: PMC10155040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma.PMID 36881002Read ↗

Genetic driver mutations introduced in identical cell-of-origin in murine glioblastoma reveal distinct immune landscapes but similar response to checkpoint blockade.Semantic proximity Read ↗

Distinct tumor immune microenvironmental (TIME) landscapes drive divergent immunotherapy responses in glioblastomaSemantic proximity Read ↗

Exploring the immune environment of glioblastoma through single-cell RNA sequencing in humanized mouse modelsSemantic proximity Read ↗

Exploring the longitudinal glioma microenvironment landscape uncovers reprogrammed pro-tumorigenic neutrophils in the bone marrow.Semantic proximity Read ↗

Deep immune profiling reveals targetable mechanisms of immune evasion in checkpoint blockade-refractory glioblastomaSemantic proximity Read ↗

Immune Microenvironment in Glioblastoma Subtypes.Semantic proximity Read ↗

Immune landscape of a genetically-engineered murine model of glioma relative to human glioma by single-cell sequencingSemantic proximity Read ↗

Exploring glioblastoma stem cell heterogeneity: Immune microenvironment modulation and therapeutic opportunitiesSemantic proximity Read ↗

Functional profiling of murine glioma models highlights targetable immune evasion phenotypes.Semantic proximity Read ↗

Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study.Semantic proximity Read ↗

Humanized glioblastoma patient-derived orthotopic xenografts recreate a locally immunosuppressed human immune ecosystem amenable to immunotherapeutic modulationSemantic proximity Read ↗

Immune landscape of a genetically engineered murine model of glioma compared with human gliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.